Bial - Portela C S.A.: Epilepsy trials

The registry lists 44 Epilepsy studies with Bial - Portela C S.A. as lead sponsor. 0 are open to participants now and 38 have results posted.

Phase 1 31Phase 2 5Phase 3 7No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Anti-epileptogenic Effects of Eslicarbazepine AcetateCompletedNCT06597084Phase 2Results posted
• Dosage Form Proportionality of Opicapone To-Be-Marketed FormulationCompletedNCT02305329Phase 1Results posted
• Food Effect and Dosage Form Proportionality Study of Eslicarbazepine AcetateCompletedNCT02288312Phase 1Results posted
• The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of WarfarinCompletedNCT02287415Phase 1Results posted
• Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine AcetateCompletedNCT02284880Phase 1Results posted
• Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and CarbamazepineCompletedNCT02284854Phase 1Results posted
• Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor FunctionCompletedNCT02284828Phase 1Results posted
• Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed FormulationCompletedNCT02283840Phase 1Results posted
• Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.CompletedNCT02283827Phase 1Results posted
• A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and TopiramateCompletedNCT02283814Phase 1Results posted
• Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac RepolarizationCompletedNCT02283788Phase 1Results posted
• Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepineCompletedNCT02281591Phase 1Results posted
• An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093CompletedNCT02281526Phase 1Results posted
• Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.CompletedNCT02281448Phase 1Results posted
• An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093CompletedNCT02281422Phase 1Results posted
• Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093CompletedNCT02279667Phase 1Results posted
• Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its MetabolitesCompletedNCT02172755Phase 1Results posted
• The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of DigoxinCompletedNCT02172742Phase 1Results posted
• A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093CompletedNCT02171234Phase 1Results posted
• A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093CompletedNCT02171195Phase 1Results posted
• The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093CompletedNCT02170649Phase 1Results posted
• A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093CompletedNCT02170077Phase 2Results posted
• Pharmacokinetics, Efficacy and Tolerability of BIA 2-093CompletedNCT02170064Phase 2Results posted
• Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative FlavoursCompletedNCT02021461Phase 2Results posted
• A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy VolunteersCompletedNCT01879345Phase 1Results posted
• A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy VolunteersCompletedNCT01879332Phase 1Results posted
• Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy VolunteersCompletedNCT01679002Phase 1Results posted
• Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy VolunteersCompletedNCT01678976Phase 1Results posted
• Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset SeizuresCompletedNCT01527513Phase 2Results posted
• Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly PatientsCompletedNCT01422720Phase 3Results posted
• Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial SeizuresCompletedNCT00988429Phase 3Results posted
• Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in ChildrenCompletedNCT00988156Phase 3Results posted
• Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy SubjectsCompletedNCT00987558Phase 1Results posted
• Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial SeizuresCompletedNCT00957684Phase 3Results posted
• Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial EpilepsyCompletedNCT00957372Phase 3Results posted
• Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial EpilepsyCompletedNCT00957047Phase 3Results posted
• Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and OxcarbazepineCompletedNCT00900237Phase 1Results posted
• Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral ContraceptiveCompletedNCT00898560Phase 1Results posted
• Bioequivalence of Two Different Sources of Eslicarbazepine AcetateCompletedNCT03116321Phase 1
• Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy VolunteersCompletedNCT02777671Phase 1
• Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset SeizuresCompletedNCT02484001Phase 3
• Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.CompletedNCT02283801Phase 1
• The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in PatientsTerminatedNCT01878578Phase 1
• Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)CompletedNCT01532726